Biotech investors’ plea to Trump, and a busy M&A week
Why it matters: Biotech investors' plea to President Trump could reshape FDA regulatory oversight for rare disease drugs.
- Biotech investors, through an industry-patient coalition including Rod Wong, sent a letter to President Trump advocating for greater FDA regulatory flexibility, influenced by recent decisions on rare disease drugs.
- Eli Lilly received U.S. approval for its obesity pill and is strategically entering the sleep medicine market.
- Large pharma companies engaged in significant deal-making and M&A activity this week.
- YouTube is seeing a strange trend of promotion for psychedelic drugs, raising questions about content moderation and public health.
Biotech investors, led by Rod Wong, are urging President Trump for increased regulatory flexibility at the FDA, citing concerns over recent rare disease drug decisions impacting investment trends. This comes amidst a busy week in pharma, with Eli Lilly expanding into sleep medicine and securing U.S. approval for its obesity pill, alongside significant M&A activity and a peculiar trend of psychedelic drug promotion on YouTube.
